Prognostic Value of PIF Detection in Embryo Culture Media Correlation With Pregnancy Outcome
Launched by BIOINCEPT LLC · Mar 1, 2013
Trial Information
Current as of June 19, 2025
Unknown status
Keywords
ClinConnect Summary
The aim of the proposed project is to investigate a non invasive biomarker, PIF (PreImplantation Factor), a 15amino acid peptide (MVRIKPGSANKPSDD) secreted only by viable embryos and placenta (Stamakin et al. RBE 2011).
PIF positive embryos will be able to grow to blastocyst stage and PIF levels could be a marker of progressive pregnancy. We will measure PIF levels in IVF culture media before embryo transfer to correlate IVF pregnancy with PIF levels. Our objective will be to define PIF as a biomarker for viable embryos in order to increase IVF success rates following SET. PIF levels will ...
Gender
FEMALE
Eligibility criteria
- Inclusion criteria:
- • All women included in our centers for classical IVF or ICSI, who will sign the written consent to participate in the study. PIF level evaluation in culture media (M) and pregnancy prognosis (S1 and S2) will be done only for women with SET.
- • Exclusion criteria Women who will refuse to participate in the program.
About Bioincept Llc
Bioincept LLC is a pioneering biopharmaceutical company dedicated to advancing innovative therapeutic solutions for unmet medical needs. With a strong focus on developing novel treatments and diagnostic tools, Bioincept leverages cutting-edge research and technology to enhance patient outcomes in oncology and other critical areas. The company is committed to conducting rigorous clinical trials that adhere to the highest regulatory standards, ensuring safety and efficacy while fostering collaboration with healthcare professionals and research institutions. Through its dedication to scientific excellence and patient-centered approaches, Bioincept aims to transform the landscape of modern medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Haven, Connecticut, United States
Poissy, Cedex, France
Paris, , France
Poissy, , France
Athens, , Greece
Patients applied
Trial Officials
Eytan R Barnea, MD, FACOG
Study Chair
BioIncept LLC
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials